The First Pile Event

The First Pile Event

The First Pile Event

Batavia Biosciences - Favicon

 Welcome to the next chapter in the evolution of biomanufacturing!

On behalf of Provast and Batavia Biomanufacturing, we invite you to join us for the groundbreaking event on May 11, 2023. This momentous occasion marks the dawn of a new era in our history, as we embark on a journey to revolutionize the biomanufacturing industry.

At this landmark event, you’ll have the opportunity to:

  • Witness the groundbreaking ceremony
  • Discover our vision and strategic plans for the future
  • Networking with peers over drinks and a bite

Don’t miss this opportunity to be a part of Batavia Biomanufacturing’s future and join us in shaping the landscape of biomanufacturing for years to come. Secure your spot now and experience firsthand the excitement and potential of Batavia Biomanufacturing.

15:45  – Walk-In
16.10  – Welcome by Hans de Jong, Partner of  Provast
16.15  – Welcome by Eize de Boer, General Manager  Batavia Biomanufacturing
16:20  –  Batavia Time Capsule
16.25 – Groundbreaking ceremony with  Wethouder Fleur Spijker
16:30 -Drinks & Snacks
18:00  – Event Conclusion

Please note: Attendance for this event is limited, so be sure to reserve your spot today. Simply click  complete the registration form to secure your spot.

Where: Robert Boyleweg, 2333 CA Leiden (View on Google Maps)

Parking: We recommend Parking Ehrenfest or Parking University Sports Center

For more information about Batavia Biomanufacturing or the groundbreaking first pile event, please contact our event coordinator at or call +31(0)610382833

Register for our Product Development Plan workshop

Register for our Product Development Plan workshop

Batavia Biosciences - Favicon

Join us at the BIO Convention for our exclusive workshop designed specifically for biotech companies to understand  your road to market.

During the workshop, we will share our expertise and industry knowledge in the development of a detailed product development plan which is pivotal to help you navigate the complexities of drug development and accelerate your path to market.

In this hands-on workshop, you will:

  • Gain a deeper understanding of the drug development process
  • Explore general challenges encountered when moving a product from bench to market
  • Understand the contents of a PDP
  • Next steps in successfully preparing your PDP

Don’t miss this unique opportunity to elevate your drug development strategy and bring your innovative therapies to patients quicker.

Date: Tuesday, June 6 from 7:30-10:30AM


Constitution Room
Seaport Hotel
1 Seaport Lane, Boston, MA 02210

Reserve your seat! Please note that it is free to register until 1 june 2023. After that date, a registration fee of $99.95  applies.

Secure your spot nowand unlock the full potential of your drug development journey.

Menzo Havenga, CEO

Menzo Havenga, CEO

Dr Menzo Havenga is a molecular virologist  with over 200 publications in international peer-reviewed scientific journals and inventor of more than 45 patents.

Menzo has worked at a variety of institutions including big pharma, biotech companies, and non-for-profit  organizations in C-suite leadership positions.

He has gained a wealth of experience in assessing businesss plans and product development plans and bringing products from early discovery to the market.

In 2010, after a successful career as head of R&D at Crucell, he launched his own company, Batavia Biosciences,  with Headquarters in the Netherlands and subsidiaries in the US and Asia. Since incoporation, he assumes the role as president and CEO of Batavia Group companies.

Batavia Biosciences to manufacture Marburg vaccine for IAVI under $35.7M DTRA grant

Leiden, the Netherlands, Nov 12, 2019 – We are proud to announce that we have partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against Marburg virus. (Link to IAVI press release)

This is the second collaboration between Batavia and IAVI on VSV vaccine development, the first being a CEPI funded award to develop a VSV-based vaccine against Lassa virus.

In both programs, Batavia leverages its highly intensified manufacturing process (HIP-Vax) technology, combined with NevoLine™ manufacturing equipment (Univercells), to manufacture clinical product for human testing and to provide a low-cost manufacturing solution for these vaccines in the future.

The VSV-Marburg vaccine candidate rVSVΔG-MARV-GP has been licensed by IAVI from the Public Health Agency of Canada and demonstrated strong protection from the deadly disease in non-human primate studies.

Marburg virus is a public health threat that has a high case fatality rate, and it is a potential bioterrorism threat. The World Health Organization has identified Marburg virus disease, along with other viral hemorrhagic fevers, as a priority for research and development because of its epidemic potential and because there are insufficient countermeasures to prevent and treat it. The U.S. Centers for Disease Control has classified Marburg virus as a Category A bioterrorism threat – a high-priority agent that poses a risk to national security.

Vendor Versus Center of Excellence

What type of CDMO is the right fit for you?

When it comes to outsourcing, there is often confusion about the type of partner that is most appropriate for a project. In our previous article, we discussed the difference between a CRO, CMO and CDMO. In this article, we would like to zoom in on the different type of CDMOs in the field of biopharmaceutical contracting.

Different types of CDMOs

The term CDMO is becoming fashionable. More and more CMOs are adding the D for development to highlight that they have more to offer than manufacturing biopharmaceuticals. However, there is a great variety in CDMOs in terms of capabilities and expertise. For example, many of the large CDMOs apply a business model focused at late-stage and commercial manufacturing.

As a result, larger CDMOs tend to offer process development services only to those companies who are willing to sign for late-stage manufacturing, which is where most of their profit is generated.  On the other hand, there are CDMOs whose primary focus is on process development rather than manufacturing. They perform GMP manufacturing only for the processes they have developed and know better than anyone.

The most notable difference in CDMOs is that between what we call a ‘vendor CDMO’ and a ‘Center of Excellence (CoE) CDMO’.

Vendor CDMO

Vendor CDMOs focus on operational excellence, meaning they’ve optimized one or more standardized processes and, as a result, are able to keep the prices for their services below market average. These companies must apply economies of scale to keep their costs and, subsequently, their prices low. This requires heavy spending on facilities and equipment to achieve efficiencies.

Projects that are an excellent fit for vendor CDMOs are those that fit their standard processes. Typically, these projects are strongly defined by nature, and commodity based. The production of a master cell bank is an example of such a project. In general, making a cell bank is very straightforward. Outsourcing such a program to a vendor CDMO is an outstanding way to cut expenses, without too much risk.

Vendor CDMOs are able to handle large volumes of such projects, because they have optimized every step of the process. Their staff is trained to repeat the same step over and over again very accurately. But what if your program doesn’t fit the platforms of these CDMOs?

Center of Excellence CDMO

When you have a unique project, requiring a company to provide knowledge to make it a success, a CoE type of CDMO would be a better fit for you. CoE CDMOs provide leadership in a certain focus area, share best practices, perform research, and provide support. Many CoE CDMOs offer consultancy services next to their process development and manufacturing capabilities.

The business model of a CoE is based on creating long-term partnerships with their customers, to whom they offer tailored services. Because this model requires hiring a highly educated and experienced staff, requires a higher level of customer intimacy, and attracts more high-risk projects, prices tend to be above the market average. In return, the customer can expect a higher level of quality, flexibility and customer service than a vendor CDMO could provide.

Product development for a new viral vector-based product typically requires a custom-developed manufacturing process. In particular, scaling up viral vector production for clinical manufacturing requires specific know-how that can only be gained from years of experience in the field.  For this reason, partnering with a CoE CDMO that specializes in viral vectors is often the wisest choice to de-risk and accelerate such programs.

Batavia Biosciences is a Center of Excellence for viral vaccine and viral vector development with extensive experience in the field of infectious diseases and oncology. Interested to learn more about what we can do to help your product development moving forward?

Interview: Menzo Havenga

Future of Vector Vaccines

Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? “Absolutely”, says expert  Menzo Havenga  (CEO, Batavia Biosciences). In an interview with a Dutch local newspaper, Menzo explains some of the benefits of the use of viral vectors, such as the stability and costs. Additionally, viral vectors have other highly promising medical applications like the development of cancer vaccines and gene therapies.

Link to article  (in Dutch)

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression